Do GLP-1 Drugs Cause Gallstones? What the Evidence Actually Shows

Gallbladder problems come up when people talk about GLP-1 medications: in our corpus of 42 distinct community reports, 4 of them — 9.5% — mention gallstones or gallbladder trouble, level with headache, ahead of dizziness and hair loss, and well behind the GI cluster. (Restated 25 September 2026 from 3 of 26 (11.5%) when ten GLP-1 communities were admitted to the report pool, taking it from 26 to 42.) (Corrected 29 August 2026: this read "14.6% of 185 distinct community reports" until we found that most of that pool came from subreddits we do not collect from, r/gallbladders chief among them — which inflated this particular figure more than any other. See the correction.) The clinical evidence behind the worry is real, but it is genuinely more mixed than either a scare headline or a reassurance suggests. This is the fourth piece in our evidence series — after which effects have enough evidence to calibrate a model, the pooled clinical rates, and what patients themselves report — and the first to walk through a single effect end to end.

Three kinds of evidence exist, and they do not all point the same way.

What the regulator-approved label says

The current US prescribing information for Wegovy (semaglutide for weight management) carries a dedicated warning section for acute gallbladder disease. Its first sentence: "Treatment with WEGOVY is associated with an increased occurrence of cholelithiasis and cholecystitis." The numbers behind it: in randomized adult weight-reduction trials, cholelithiasis (gallstones) was reported by 1.6% of injection-treated patients versus 0.7% on placebo, and by 2.5% versus 1% for the tablet form.

The label also addresses the obvious confounder head-on: "Substantial or rapid weight loss can increase the risk of cholelithiasis; however, the incidence of acute gallbladder disease was greater in WEGOVY-treated patients than in placebo-treated patients, even after accounting for the degree of weight loss." In other words, the manufacturer's own analysis says this is not solely a fast-weight-loss artefact. (Quoted from the current US prescribing information via DailyMed, accessed 26 August 2026.)

What a meta-analysis of 76 randomized trials says

A systematic review and meta-analysis published in JAMA Internal Medicine in 2022 (He et al.) pooled 76 randomized trials with 103,371 patients. Randomization to a GLP-1 receptor agonist was associated with an increased risk of gallbladder or biliary disease overall (relative risk 1.37, 95% CI 1.23–1.52), and of cholelithiasis specifically (RR 1.27, 95% CI 1.10–1.47).

Two of its interaction findings matter most for weight-management patients. The association was markedly stronger in weight-loss trials (RR 2.29, 95% CI 1.64–3.18) than in diabetes trials (RR 1.27). And it was concentrated at higher doses (RR 1.56, vs 0.99 at lower doses) and longer duration of use (RR 1.40, vs 0.79 for shorter use). Weight-management dosing is exactly the higher-dose, longer-duration end of that spectrum.

What a large new cohort study found — in the other direction

In December 2025, a retrospective cohort study in the Journal of Clinical Medicine (Kazi et al., PMID 41464784) used the TriNetX global health-records network to compare adults who have both type 2 diabetes and inflammatory bowel disease — a population at elevated baseline risk of biliary complications — with and without GLP-1/GIP therapy: 16,026 users propensity-matched to 16,026 non-users. Cholelithiasis occurred in 3.5% of GLP-1/GIP users versus 6.3% of non-users; cholecystitis in 0.8% versus 2.2%. The authors conclude that in this population the drugs "are associated with substantially reduced risks of gallstone-related complications."

Hold the caveats alongside the headline: this is retrospective, outcomes are ICD-10-coded rather than adjudicated, and the population — diabetic patients with bowel disease — is not the typical weight-loss patient. One matched cohort does not overturn a meta-analysis of 76 randomized trials. But it is a 32,052-patient data point that the association is not one-directional in every population, and the authors' call for prospective, agent-specific studies is the right one.

How can both be true?

Different populations. The label figure and the meta-analysis describe mostly weight-management and diabetes trial populations against placebo; the 2025 cohort describes a specific high-baseline-risk group against routine care. "Compared to what, in whom" changes the answer.

Dose and duration. The meta-analysis found the risk concentrated at higher doses and longer use — so a single pooled number understates the range across regimens.

Rapid weight loss itself causes gallstones. Losing weight quickly is an independent, well-established gallstone risk factor regardless of how the weight is lost — though the label's analysis found the drug association persisted even after accounting for it.

The honest summary: "do GLP-1s cause gallstones" does not have one number. Randomized-trial evidence says risk goes up, most clearly at weight-loss doses over longer periods — from a low base (1.6% vs 0.7% in the label's trials). At least one large real-world population shows the opposite direction. Anyone quoting a single percentage without naming its population is compressing away the part that matters.

What our own evidence base holds (as of 10 September 2026)

Our database held 83 gallstone-tagged data points when this section was read on 10 September 2026 (92 on 14 September), most of them deliberately rate-less — case reports, regulatory warnings, and mechanism papers that discuss the effect without stating a comparable incidence figure, which our extraction rules refuse to force a number onto. The eligible clinical rate base was then 11 stated rates from 4 studies, pooling to 1.7% (95% CI 0–6%), source diversity graded "moderate".

Update, 14 September 2026 (21:56 BST). On 11 September 2026 the trial-registry re-collection running that week added two orforglipron trials whose non-serious events tables post cholelithiasis — NCT05971940, three arms at 0.7%, 1.5% and 0% (n=143, 137 and 141), and NCT05931380, three arms at 0%, 0% and 1.7% (n=61, 57 and 60); our per-source list shows each as its arm average, 0.7% and 0.6% — so the gallstones endpoint published, until 15 September 2026, 17 stated rates from 6 distinct studies (9 source entries, because SURMOUNT-1, SELECT and STEP 1 each post cholelithiasis and cholecystitis separately), pooling to 1.7% (95% CI 1–5%), still "moderate"; at 10:39 BST on 15 September 2026, until later registry batches moved it, it published 20 stated rates from 7 distinct studies (10 source entries), the pooled figure and interval unchanged; as of 05:53 UTC on 30 September 2026, until later registry batches moved it, it published 24 stated rates from 8 distinct studies (11 source entries), still 1.7% (95% CI 1–5%) and "moderate"; as of 19:15 UTC on 3 October 2026, until later registry batches moved it, it published 28 stated rates from 10 distinct studies (13 source entries), still 1.7% (95% CI 1–4%), now "high" — the two studies added in that step are Japanese dulaglutide registry trials, neither a serious-only figure; as of 20:45 UTC on 16 October 2026 it publishes 36 stated rates from 13 distinct studies (16 source entries), still 1.7% (95% CI 1–4%) and "high", with serious-only figures still three of the thirteen sources. Three of the six sources at the 14 September reading (three of seven on 15 September) are the serious-adverse-event floors described next; the table below is unchanged and still correct for the trials it names.

Three of those studies — three of the four read on 10 September, three of the six on 14 September — are serious-adverse-event rates, and that changes how the number should be read. ClinicalTrials.gov posts two separate tables per trial: serious adverse events, and other (non-serious) events above the trial's own reporting threshold — usually 5%. Gallbladder events are adjudicated serious and fall well below 5%, so for these three trials the SAE table is the only place a gallstone number is posted. Their arm rates:

Counts read from each trial's own results table on 10 September 2026; every rate above is the registry's own arithmetic, not ours.

A serious-AE count is a floor on all-cause incidence, not incidence itself — a patient whose gallstones never required hospitalisation or intervention is not in these numerators. That is exactly why the pooled 1.7% sits below the label's 1.6%-versus-0.7% all-cause figure in some arms and near it in others, and why the fourth source on 10 September — the 2025 TriNetX cohort's 3.5%, a genuine all-cause figure — sits above all of them. The API marks each source rateKind: "incidence" or "serious_ae" so the distinction survives into anything built on our data, and the pooled figure carries the same sentence beside it wherever it is published.

Worth showing rather than hiding: this base has moved three times in three weeks. It was single-source at 1.6% until 26 August 2026; a second source took it to 3.4%; then the 31 August seed correction found that the STEP-1 row behind the 1.6% was one of 150 April-2026 rows restating our own static table under a real trial URL that no extraction had ever read, and withdrawing it left a single source at 3.5%. The 11 rates read on 10 September were the first registry-sourced gallstone figures in the base. (Correction, 10 September 2026: this section published "4 stated rates from 2 distinct sources, pooling to 3.4%" from 26 August until today, including the ten days after the 31 August withdrawal had already reduced it to one source — the seed sweep corrected the corpus and the pooled-rates table and never re-read this article. The current figures above are from a live read of the endpoint linked below.) Gallstones remains below the 10-point bar we require for a fully calibrated statistical model, and the community track's 9.5% (4 of 42 reports; 3 of 26 until 25 September 2026) is a reporting frequency, not an incidence rate — we never blend the two.

Check the live numbers yourself: the gallstones endpoint serves the current pooled estimate, every source with its URL, and both tracks, updated as the corpus grows.

If you are on a GLP-1 now

This is educational content, not medical advice. Gallbladder symptoms — persistent pain in the upper right abdomen (especially after fatty meals), pain with fever, or yellowing of the skin or eyes — warrant prompt medical attention. The label's own instruction to clinicians is that if cholelithiasis is suspected, gallbladder studies and clinical follow-up are indicated. Most people on these medications never develop gallstones; in the label's own trials the absolute rate was 1.6%, against 0.7% on placebo.

Query everything behind this article — all 15 effects, both tracks, every source — at magistra.health/en/data-api, with the full eligibility methodology at magistra.health/en/methodology.